Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), José Baselga(Novartis (Switzerland)), Ahmet Zehir(Natera (United States)), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Philip Jonsson(Memorial Sloan Kettering Cancer Center), Ashwin Kishtagari(Memorial Sloan Kettering Cancer Center), David M. Hyman(Memorial Sloan Kettering Cancer Center), Aijazuddin Syed(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center)
Cited by 851
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k